Search Results for "donepezil"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for donepezil. Results 11 to 15 of 15 total matches.
See also: Aricept

Donanemab (Kisunla) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
— The acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine and the NMDA-receptor antagonist memantine ...
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia. Donanemab is the third IV amyloid beta-directed monoclonal antibody to be marketed in the US. Lecanemab (Leqembi – Biogen/Eisai) was approved by the FDA in 2023 for the same indication as donanemab. Aducanumab (Aduhelm – Lilly) was granted accelerated approval in 2021, but it was withdrawn from the market...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):129-31   doi:10.58347/tml.2024.1709a |  Show IntroductionHide Introduction

A Rivastigmine Patch for Dementia

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008  (Issue 1282)
Donepezil – Aricept (Esai/Pfizer) 5 or 10 mg tabs 5-10 mg once 5 mg once/d; after 4-6 wks $181.50 Aricept ...
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system (Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for treatment of mild to moderate dementia associated with Alzheimer's or Parkinson's disease. An oral formulation of rivastigmine tartrate has been available in the US since 2000,2 but gastrointestinal adverse effects possibly related to rapidly rising serum concentrations have limited its use.
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-2 |  Show IntroductionHide Introduction

Solifenacin and Darifenacin for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005  (Issue 1204)
such as donepezil (Aricept) used to treat Alzheimer’s disease and anticholinergic drugs may interfere with each ...
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Med Lett Drugs Ther. 2005 Mar 14;47(1204):23-4 |  Show IntroductionHide Introduction

Lecanemab (Leqembi) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
— The acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine, the NMDA-receptor antagonist memantine ...
Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment...
Med Lett Drugs Ther. 2023 Feb 6;65(1669):17-8   doi:10.58347/tml.2023.1669a |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
OF DEMENTIA — The oral acetylcholinesterase inhibitors donepezil (Aricept, and generics), rivastigmine ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction